Tonix Q3: TONMYA Sales $15.0M, Net Loss Widens to $53.3M, Runway to Early Q3 2027
TNXP is trading near its 52-week low of $4.55 (9.9% below the low).
Summary
Tonix reported Q3 TONMYA net sales of $15.0 million, up 37% sequentially, alongside a $53.3 million net loss as commercialization spending ramped. Cash of $162.8 million is now expected to last into early Q3 2027.
Key Events · Earnings and Guidance · TNXP
-
TONMYA Sales Up 37% Sequentially
Q3 2026 TONMYA net sales were approximately $15.0 million; total product revenue was $17.2 million versus $3.3 million a year earlier. Total prescriptions rose 28% quarter-over-quarter to 16,375.
-
Net Loss Widens on Commercial Spend
Net loss available to common stockholders was $53.3 million, or $2.89 per share, versus $32.0 million a year ago. R&D rose to $25.8 million from $9.3 million and SG&A to $45.6 million from $25.7 million.
-
Cash Runway Extended to Early Q3 2027
Cash and equivalents were $162.8 million at September 30, 2026, plus about $1.5 million raised from equity offerings since. Net cash used in operations was $125.6 million for the nine months ended September 30, 2026.
-
Patent Challenge Still Unresolved
The release reiterates the October 2, 2026 disclosure that Dr. Reddy's filed an ANDA with a Paragraph IV certification for a generic TONMYA; Tonix says it intends to enforce its IP but cannot predict the outcome.
Analysis · TNXP · Life Sciences
TONMYA is growing fast — $15.0 million in Q3 net sales, up 37% from Q2, with total prescriptions up 28% to 16,375 — but the cost of building that franchise is steep. R&D jumped to $25.8 million from $9.3 million and SG&A to $45.6 million from $25.7 million, pushing the quarterly net loss to $53.3 million from $32.0 million a year ago. The offsetting positive is the balance sheet: $162.8 million in cash at September 30 plus $1.5 million raised since, which management says funds operations into early Q3 2027 — roughly a quarter longer than the early-Q2-2027 runway disclosed in the August 10-Q. That buys time, but the burn rate ($125.6 million used in operations over nine months) means another raise is likely before the runway ends, and the Dr. Reddy's Paragraph IV challenge to TONMYA's patents remains an unresolved overhang.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TNXP was trading at $4.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $81.3M. The 52-week trading range was $4.55 to $20.56. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.